Moderna Inc (XSWX:MRNA)
CHF 58.54 +0.73 (+1.26%) Market Cap: 25.61 Bil Enterprise Value: 22.45 Bil PE Ratio: 0 PB Ratio: 3.93 GF Score: 62/100

Moderna Inc at Piper Sandler Healthcare Conference Transcript

Dec 02, 2025 / 04:00PM GMT
Edward Tenthoff
Piper Jaffray Inc - Analyst

Next presenting company Moderna. My name is Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and Moderna that are listed at the back of the room and also at the registration desk.

So as you know, Moderna is the leading developer of messenger RNA vaccines and medicines. Moderna's shares have been under pressure over the last couple of years after really helping us through the COVID pandemic in part as a result of decreasing immunization rate. I got my next -- my [mNEXSPIKE] vaccine. I think anyone gets a flu shot should get a COVID vaccine as well as long as they're recommended by their doctor.

And now under the FDA and RFK Jr., it really feels like they've declared war on mRNA vaccines and then we recently have the setback with the -- victory. So it's been a tough slog here. But you guys just recently had an R&D Day and we're pointed to all of the new vaccines and medicines that are coming -- and I think it's a really

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot